Pharma gets social: Top-10 pharma social media firsts in 2013
December 14, 2012
As 2013 draws to a close, I have put together a list of my top-ten favourite pharma social media ‘firsts’ of the year – new things that pharmaceutical companies have been doing in social media.
It’s been a year packed with new ideas, channels, and lessons learned. The top-ten firsts I have included in my list are not necessarily the most successful social media initiatives, but every case, whether through purposeful innovation or accident, is an opportunity for us all to keep learning.
In pharma social media, this list is where the new ground is being taken in what is still a challenging environment for regulated pharmaceutical industry.
Here’s what pharma did for the first time in 2013:
10. Cleaned up its Twitter name
Pfizer cleaned up its Twitter name this year by acquiring the rights to @pfizer, which replaced the somewhat awkward @pfizer_news handle it had been using for its official Twitter presence since joining the platform in 2009. Four years ago, the company was too late in the Twitter game to register its own name, which had already been taken. Now, with the name reclaimed, tweets from @pfizer really are from Pfizer.
In a statement, Pfizer said the name change reflects the broad nature of official content it shares on Twitter: “…our content won’t be changing – our Twitter handle will just more accurately reflect the scope of what we’re sharing.”
9. Implemented Tumblr to support patients
This year, Janssen launched an initiative on social networking site Tumblr to engage people living with HIV. The “Positively Together” Tumblr profile encourages users to “Share Your Stories” and includes a range of media on the HIV theme.
“This year, Janssen launched an initiative on social networking site Tumblr to engage people living with HIV.”
Content shared by other users is vetted before being accepted, and must comply with Janssen’s guidelines. “The content contained on this site comes from members of the public and does not necessarily reflect the views of Janssen, and no endorsement or approval of their content should be implied”, read the content guidelines. As it happens, most of the current content to date has been shared by the Positively Together team, indicating that perhaps the initiative has yet to gain real traction on Tumblr.
Tumblr is a microblogging website for sharing images, video, music and comments that has over 100 million users and boasts around 70 billion posts. That’s a lot smaller than the number of users on Facebook, but with reports this year that US teenagers are moving away from Facebook in favour of other platforms like Tumblr, Janssen might just be on to something. My guess is that the company is a little ahead of its time, but that’s not a bad thing at all.
8. Exceeded 7 million views on YouTube
Figure 3: Johnson & Johnson’s YouTube Health Channel features the company’s
‘For All You Love’ campaign
Johnson & Johnson has provided many social media firsts in the past, and here’s one that comes after years of pioneering engagement: in 2013, the total number of video views on the company’s YouTubechannel exceeded seven million.
This year alone, Johnson & Johnson has already added 77 new videos to the channel, which have contributed almost 50,000 new views. And its extensive legacy of content continues to engage – the three most popular videos on the channel have been viewed a total of almost 1.5m times between them.
To be fair, although I have often referenced the company’s innovation in social media, Johnson & Johnson’s products span far more areas of healthcare than pharmaceuticals, and its consumer health brands provide a friendly face for engagement.
“This year alone, Johnson & Johnson has already added 77 new videos to the channel, which have contributed almost 50,000 new views.”
Currently on the channel’s home page is a video from Johnson & Johnson’s current “For All You Love”campaign which its VP Global Corporate Affairs, Michael Sneed, says is “a campaign that emphasizes our strategy for reconnecting with consumers”. The campaign features an easy-listening rendition of Guns N’ Roses 1980’s rock hit ‘Sweet Child O’ Mine’, sung by London-based Capital Children’s Choir. Repurposing a rebellious hard rock anthem to reconnect with consumers – that’s another pharma social media first.
7. Reached 90,000 likes on Facebook
Figure 4: GSK uses Facebook to actively engage 90,000 followers
Back in 2011 I wrote about GlaxoSmithKline’s proactive engagement on Facebook, during a season in which only the bravest communicators would open up two-way dialogue with consumers online. By the time you read this, the number of ‘Likes’ on the company’s Facebook page will have exceeded 90,000, and continues to grow at over 500 likes per week.
A little ahead of GSK in followers, Pfizer’s Facebook page has also recently passed the 90,000 Likes threshold. These figures put GSK and Pfizer ahead of other pharma leaders on Facebook such as Boehringer Ingelheim, which currently has around 82,000 likes, but is growing rapidly. The race is on to hit 100,000.
“These figures put GSK and Pfizer ahead of other pharma leaders on Facebook such as Boehringer Ingelheim, which currently has around 82,000 likes, but is growing rapidly.”
In truth of course, the prize in pharma social media is not for follower counts but for meaningful engagement that connects companies with stakeholders. That’s a story for another day.
6. Integrated social media with a prescription product website
Figure 5: Novartis’ Gilenya website and social media strategy is targeted at younger MS patients based in the US
This year, Novartis launched a product website for Gilenya that integrates with open social media channels like Twitter, Facebook and YouTube to reach out to patients in the United States with Multiple Sclerosis (MS).
“One reason we have never before seen social media used to openly support a branded prescription product is because in most countries outside the US, it would be illegal.”
One reason we have never before seen social media used to openly support a branded prescription product is because in most countries outside the US, it would be illegal. Novartis has overcome this by configuring its Facebook and YouTube channels so that users outside of the US are unable to access them; while its Twitter channel includes “USOnly” in its profile name and description, and as a hashtag on every tweet. The product website states “For US Residents Only“, while non-US residents are directed to Novartis’ global corporate site.
The social media components are cautiously implemented, with limited opportunity for two-way engagement. But in launching the Gilenya site, Novartis has taken a lead among pharmaceutical companies to proactively navigate the industry’s sensitive regulatory environment. This is a big step toward providing the kind of engagement that consumers value in the digital age.
5. Lost $160m in a social media crisis
Figure 6: Chinese comedian Song Dandan’s apology on Weibo for his role in the TV ad for Renhe’s product
I have included Chinese pharmaceutical company Renhe Pharma’s social media crisis in my top-10 firsts, not for its innovative engagement strategy, but for its value as an illustration of the power of social media in healthcare and the significant role of doctors online. It is a painful example of what can go wrong when social media is used against a pharmaceutical brand.
“It is a painful example of what can go wrong when social media is used against a pharmaceutical brand.”
Earlier this year, Renhe Pharmacy lost 10% in stock value after a doctor shared misinformation via a 140-character post on Chinese social media site Sina Weibo.
According to South China Morning Post, a Beijing-based doctor posted a message on Weibo that read: “Youkadan and Haowawa medicine have been proven toxic to children’s livers. Children under one year should absolutely not take it. Children under six should take it with caution.”
He then encouraged high-profile users to share his post: “Why are their advertisements still in the media? Celebrities, please spread the message and have these commercials withdrawn.” The post was immediately shared, tens of thousands of times, by others including a Chinese television star who at the time had over 26 million followers.
Popular Chinese comedian Song Dandan, who starred in a Chinese television ad for the medicine, posted an apology on Weibo for his role in advertising the medicine and vowed never again to support drug advertising.
Although the doctor who originally posted the message later admitted that he had inadequate information, and China’s Food and Drug Administration issued a statement claiming the medicine was safe, it was too late to prevent the impact on Renhe’s share price, and the company estimated it lost around one billion yuan (USD $160m).
It is not the first time that a pharmaceutical company’s stock has crashed after a social media crisis. In 2011, K-V Pharmaceuticals‘ share value dropped 20% after a Facebook user launched a protest page about its product pricing, and in that case, doctors joined in the online campaign via the Facebook page. What is significant about this year’s Renhe crash is that the crisis was started by a healthcare professional’s social media post.
4. Maximised congress activity with social media
Earlier this year I wrote about pharmaceutical companies engaging oncologists via social media at the Annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, and reviewed the use of congress hashtag #ASCO13 by GSK and Genentech. At ASCO, Novartis was the most prolific tweeter, sending 76 tweets, while Roche was mentioned the most by others, being mentioned over 280 times on the congress Twitter hashtag.
This trend has developed throughout the year, as pharmaceutical companies have embraced the opportunity to make the most of their congress activity, taking engagement well beyond the physical event to connect with customers worldwide through congress hashtags in social media.
3. Hosted disease-focused chats on Twitter
Boehringer Ingelheim took things a step further in their social media engagement at the European Respiratory Society’s annual congress, becoming the first pharmaceutical company to host a disease-focused Twitter chat.
“We’ll be chatting about the unmet medical and patient need in COPD, the importance for new treatment options and what could be done to improve patient care and disease outcomes“, read Boehringer Ingelheim’s announcement about the Twitter chat.
“The Twitter chat used hashtag #COPDChat to host a conversation with people all over the world on Twitter.”
The Twitter chat used hashtag #COPDChat to host a conversation with people all over the world on Twitter. In the event, the live chat included 60 people in the conversation, which spanned from the US and Canada to South America, Europe and Asia.
2. Trained doctors in social media
Figure 7: Campus Sanofi includes a course on LinkedIn for doctors
The trend in pharmaceutical companies helping doctors to develop their social media skills started some years ago, but I am including it as a ‘first’ in 2013 because I sensed a significant growth in this year as pharmaceutical companies recognise the opportunity to support and learn from healthcare professionals online.
Earlier in the year I reported on Campus Sanofi, the online training programme that equips healthcare professionals in Spain and Portugal to use LinkedIn and other social media channels. According to Xavier Olba, Digital Strategy Manager for Sanofi Iberia, digital channels play an essential part in the work of healthcare professionals: “86% of healthcare professionals use the Internet every day as a professional tool,” he said. “The need is to make things more efficient, to support the healthcare system. Digital tools will provide for this need.”
1. Activated Digital Opinion Leaders
This year has seen breakthroughs in the activation of Digital Opinion Leaders (DOLs), key online influencers including healthcare professionals who use social media to engage other health stakeholders. In 2012 I wrote about the opportunity to activate DOLs by identifying online influencers and collaborating with them online toward mutual goals.
Boehringer Ingelheim provided my favourite example of DOL activation in 2013, and a first for pharma when it collaborated with Professor Andrew McIvor, introducing him to the online community of people interested in COPD through a hosted twitter chat during the European Respiratory Society congress.
Boehringer Ingelheim’s collaboration with Prof. McIvor was not only a pharma first but certainly a first for this emerging Digital Opinion Leader too. “Thank you for joining us, we’re pioneers!” he tweeted at the end of the chat.
We all keep learning
My congratulations and thanks to the pioneers of all these top-10 initiatives I have mentioned. Finding the right path in social media is difficult, sometimes risky, but it’s an adventure we all keep learning from. I look forward to 2014 with anticipation of many more new social media breakthroughs and I will try to keep up with them in this column.